PKR inhibitors, thus are emerging as novel drugs to treat T2D, metabolic disorders, and cancer; however, extensive research is needed to fully understand the underlying mechanism of action of these inhibitors. This evidence concerns the gene EIF2AK2 and metabolic disease.